Floatz logo

Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester)

Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2/3Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

246 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE
Fred Hutchinson Cancer Center
Phase 2/3BBB
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Vincristine sulfate
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) is also rated in:

acute myeloid leukemiaActive
B
Indicative · Phase 3
59 / 100
View asset →
leukemiaDormant
B
Indicative · Phase 2
58 / 100
View asset →
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →